Alto Neuroscience Inc's Comment on Sales, Marketing and Customers
The company serves customers who bill federal programs for products, including healthcare benefit programs and private third-party payors. Its healthcare provider clients include physicians—such as doctors, dentists, optometrists, podiatrists, and chiropractors—non-physician practitioners like physician assistants and nurse practitioners, and teaching hospitals. Covered entities subject to HIPAA regulations include health plans, healthcare clearinghouses, certain healthcare providers, and their business associates and subcontractors. The markets served encompass federal healthcare programs, including Medicare, Medicaid, and the Children’s Health Insurance Program.
In the ever-evolving landscape of biotechnology and pharmaceuticals, the spotlight often shines brightly on companies that promise innovative solutions to pressing health challenges. Alto Neuroscience, Inc., a biotech firm listed on the New York Stock Exchange under the ticker symbol ANRO, recently found itself at the center of significant legal scrutiny, a development that is raising alarm bells among its investors. Two primary legal actions have come to the forefront, spotlighting potential securities violations related to the company s initial public offering (IPO) and subsequent stock performance. Background on Alto NeuroscienceFounded with the vision of addressing neurological disorders through innovati...
The Crucial Deadline for Alto Neuroscience Investors: A Call to Action from Rosen Law FirmIn a world where the stock market constantly fluctuates, investors in Alto Neuroscience, Inc. (NYSE: ANRO) face a pivotal moment. As the company’s shares have garnered attention for lagging behind the overall market throughout August, the time to act is now. The Rosen Law Firm, an esteemed global investor rights law firm, has reminded stakeholders of an impending lead plaintiff deadline in a significant securities class action September 19, 2025.For those who purchased common stock of Alto Neuroscience, Inc. during its initial public offering (IPO) on February 2, 2024, or acquired securities during the interval from ...
Mountain View, Calif. - Alto Neuroscience, a clinical-stage biopharmaceutical company dedicated to developing pioneering precision medicines for neuropsychiatric disorders, proudly announces the successful completion of patient enrollment in its Phase 2b study evaluating ALTO-100 in adults diagnosed with major depressive disorder (MDD). With topline results projected to be released in October 2024, this milestone marks an important achievement in the advancement of innovative treatments for MDD.Major depressive disorder, a mental health condition affecting millions worldwide, poses significant challenges for patients and healthcare providers. Alto Neuroscience s ALTO-100 represents a potential breakthrough c...
Alto Neuroscience Ventures into Phase 2 Study of ALTO-101: A Groundbreaking Treatment for Cognitive Impairment in Schizophrenia LOS ALTOS, Calif. - Alto Neuroscience, a leading biotech company, has recently launched a pivotal Phase 2 clinical trial for its groundbreaking drug, ALTO-101. This transdermal formula, a novel phosphodiesterase-4 (PDE4) inhibitor, seeks to address and alleviate cognitive impairment associated with schizophrenia (CIAS). The company anticipates sharing top-line results from this study in the latter half of 2025, fostering hope for the millions affected by this debilitating condition.Cognitive impairment is a significant challenge for individuals living with schizophrenia. While antip...
Alto Neuroscience Announces Robust Q1 2024 Financial Results and Impressive Pipeline Progress LOS ALTOS, Calif. Amid the dynamic landscape of biopharmaceutical innovations, Alto Neuroscience, Inc. (NYSE: ANRO) recently showcased a formidable start to 2024 by reporting financial results for the first quarter that ended on March 31, 2024. The period marked a significant phase in the company s journey as it underscored substantial advancements in its mission to develop personalized therapies for brain disorders. Financial Overview Alto Neuroscience’s Q1 2024 financial performance highlights a solid foundation geared for future growth and development. While exact financial figures were not disclosed in the...
Alto Neuroscience Inc’s Comment on Sales, Marketing and Customers
The company serves customers who bill federal programs for products, including healthcare benefit programs and private third-party payors. Its healthcare provider clients include physicians—such as doctors, dentists, optometrists, podiatrists, and chiropractors—non-physician practitioners like physician assistants and nurse practitioners, and teaching hospitals. Covered entities subject to HIPAA regulations include health plans, healthcare clearinghouses, certain healthcare providers, and their business associates and subcontractors. The markets served encompass federal healthcare programs, including Medicare, Medicaid, and the Children’s Health Insurance Program.
Sources:
Alto Neuroscience Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Alto Neuroscience Inc’s corporate clients.
For your research, we’ve provided 9 tables on Alto Neuroscience Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
